MedTrace Logo

The Effect of Metformin in Patients With Metastatic Castration-resistant Prostate Cancer

NCT04926155 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 234

Last updated 2021-06-14

No results posted yet for this study

Summary

The purpose of this study is to assess the effect of the addition of metformin to abiraterone on survival in patients with metastatic castration-resistant prostate cancer (mCRPC). The half the patients will receive metformin in combination with androgen deprivation therapy (ADT) and abiraterone, and the other half will receive ADT and abiraterone only.

Conditions

Interventions

DRUG

Metformin

The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Yonghong Li, M.D. · Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-23
Primary Completion
2024-04-30
Completion
2024-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04926155 on ClinicalTrials.gov